NELFINAVIR MESYLATE - Generic Drug Details

✉ Email this page to a colleague

What are the generic drug sources for nelfinavir mesylate and what is the scope of freedom to operate?

Nelfinavir mesylate is the generic ingredient in one branded drug marketed by Agouron Pharms and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for nelfinavir mesylate. One supplier is listed for this compound.

Summary for NELFINAVIR MESYLATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	3
Drug Master File Entries:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	67
Clinical Trials:	86
Patent Applications:	5,949
What excipients (inactive ingredients) are in NELFINAVIR MESYLATE?	NELFINAVIR MESYLATE excipients list
DailyMed Link:	NELFINAVIR MESYLATE at DailyMed

Recent Clinical Trials for NELFINAVIR MESYLATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	Phase 1
University of Washington	Phase 2
University of Arkansas	Phase 2

See all NELFINAVIR MESYLATE clinical trials

Pharmacology for NELFINAVIR MESYLATE

Drug Class	Protease Inhibitor
Mechanism of Action	Cytochrome P450 3A Inhibitors HIV Protease Inhibitors

Medical Subject Heading (MeSH) Categories for NELFINAVIR MESYLATE

HIV Protease Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for NELFINAVIR MESYLATE

J05AE	Protease inhibitors
J05A	DIRECT ACTING ANTIVIRALS
J05	ANTIVIRALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for NELFINAVIR MESYLATE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for NELFINAVIR MESYLATE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	020779-001	Mar 14, 1997	⤷ Sign Up	⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	⤷ Sign Up	⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	⤷ Sign Up	⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	TABLET;ORAL	021503-001	Apr 30, 2003	⤷ Sign Up	⤷ Sign Up
Agouron Pharms	VIRACEPT	nelfinavir mesylate	POWDER;ORAL	020778-001	Mar 14, 1997	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.